CONTEXT: Sepsis is a common and severe complication in premature neonates, particularly those with very low birth weight (VLBW) (<1500 g). Whether lactoferrin, a mammalian milk glycoprotein involved in innate immune host defenses, can reduce the incidence of sepsis is unknown. In animal models, the probiotic Lactobacillus rhamnosus GG (LGG) enhances the activity of lactoferrin but has not been studied in human infants.OBJECTIVE: To establish whether bovine lactoferrin (BLF), alone or in combination with LGG, reduces the incidence of late-onset sepsis in VLBW neonates.DESIGN, SETTING, AND PATIENTS: Prospective, multicenter, double-blind, placebo-controlled, randomized trial conducted in 11 Italian tertiary neonatal intensive care units. Patients were 472 VLBW infants enrolled from October 1, 2007, through July 31, 2008, and assessed until discharge for development of sepsis.INTERVENTION: Infants were randomly assigned to receive orally administered BLF (100 mg/d) alone (n = 153), BLF plus LGG (6 x 10(9) colony-forming units/d) (n = 151), or placebo (n = 168) from birth until day 30 of life (day 45 for neonates <1000 g at birth).MAIN OUTCOME MEASURE: First episode of late-onset sepsis, ie, sepsis occurring more than 72 hours after birth with isolation of any pathogen from blood or from peritoneal or cerebrospinal fluid.RESULTS: Demographic, clinical, and management characteristics of the 3 groups were similar, including type of feeding and intake of maternal milk. Incidence of late-onset sepsis was significantly lower in the BLF and BLF plus LGG groups (9/153 [5.9%] and 7/151 [4.6%], respectively) than in the control group receiving placebo (29/168 [17.3%]) (risk ratio, 0.34; 95% confidence interval, 0.17-0.70; P = .002 for BLF vs control and risk ratio, 0.27; 95% confidence interval, 0.12-0.60; P < .001 for BLF plus LGG vs control). The decrease occurred for both bacterial and fungal sepsis. No adverse effects or intolerances to treatment occurred.CONCLUSION: Compared with placebo, BLF supplementation alone or in combination with LGG reduced the incidence of a first episode of late-onset sepsis in VLBW neonates.

Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial / Manzoni, P; Rinaldi, M; Cattani, S; Pugni, L; Romeo, Mg; Messner, H; Stolfi, I; Decembrino, L; Laforgia, N; Vagnarelli, F; Memo, L; Bordignon, L; Saia, Os; Maule, M; Gallo, E; Mostert, M; Magnani, C; Quercia, M; Bollani, L; Pedicino, R; Renzullo, L; Betta, P; Mosca, F; Ferrari, Fabrizio; Magaldi, R; Stronati, M; Farina, D; Italian Task Force for the, Study; Prevention of Neonatal Fungal Infections Italian Society of, Neonatology. - In: JAMA. - ISSN 0098-7484. - STAMPA. - 302:(2009), pp. 1421-1428. [10.1001/jama.2009.1403]

Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial.

FERRARI, Fabrizio;
2009

Abstract

CONTEXT: Sepsis is a common and severe complication in premature neonates, particularly those with very low birth weight (VLBW) (<1500 g). Whether lactoferrin, a mammalian milk glycoprotein involved in innate immune host defenses, can reduce the incidence of sepsis is unknown. In animal models, the probiotic Lactobacillus rhamnosus GG (LGG) enhances the activity of lactoferrin but has not been studied in human infants.OBJECTIVE: To establish whether bovine lactoferrin (BLF), alone or in combination with LGG, reduces the incidence of late-onset sepsis in VLBW neonates.DESIGN, SETTING, AND PATIENTS: Prospective, multicenter, double-blind, placebo-controlled, randomized trial conducted in 11 Italian tertiary neonatal intensive care units. Patients were 472 VLBW infants enrolled from October 1, 2007, through July 31, 2008, and assessed until discharge for development of sepsis.INTERVENTION: Infants were randomly assigned to receive orally administered BLF (100 mg/d) alone (n = 153), BLF plus LGG (6 x 10(9) colony-forming units/d) (n = 151), or placebo (n = 168) from birth until day 30 of life (day 45 for neonates <1000 g at birth).MAIN OUTCOME MEASURE: First episode of late-onset sepsis, ie, sepsis occurring more than 72 hours after birth with isolation of any pathogen from blood or from peritoneal or cerebrospinal fluid.RESULTS: Demographic, clinical, and management characteristics of the 3 groups were similar, including type of feeding and intake of maternal milk. Incidence of late-onset sepsis was significantly lower in the BLF and BLF plus LGG groups (9/153 [5.9%] and 7/151 [4.6%], respectively) than in the control group receiving placebo (29/168 [17.3%]) (risk ratio, 0.34; 95% confidence interval, 0.17-0.70; P = .002 for BLF vs control and risk ratio, 0.27; 95% confidence interval, 0.12-0.60; P < .001 for BLF plus LGG vs control). The decrease occurred for both bacterial and fungal sepsis. No adverse effects or intolerances to treatment occurred.CONCLUSION: Compared with placebo, BLF supplementation alone or in combination with LGG reduced the incidence of a first episode of late-onset sepsis in VLBW neonates.
302
1421
1428
Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial / Manzoni, P; Rinaldi, M; Cattani, S; Pugni, L; Romeo, Mg; Messner, H; Stolfi, I; Decembrino, L; Laforgia, N; Vagnarelli, F; Memo, L; Bordignon, L; Saia, Os; Maule, M; Gallo, E; Mostert, M; Magnani, C; Quercia, M; Bollani, L; Pedicino, R; Renzullo, L; Betta, P; Mosca, F; Ferrari, Fabrizio; Magaldi, R; Stronati, M; Farina, D; Italian Task Force for the, Study; Prevention of Neonatal Fungal Infections Italian Society of, Neonatology. - In: JAMA. - ISSN 0098-7484. - STAMPA. - 302:(2009), pp. 1421-1428. [10.1001/jama.2009.1403]
Manzoni, P; Rinaldi, M; Cattani, S; Pugni, L; Romeo, Mg; Messner, H; Stolfi, I; Decembrino, L; Laforgia, N; Vagnarelli, F; Memo, L; Bordignon, L; Saia, Os; Maule, M; Gallo, E; Mostert, M; Magnani, C; Quercia, M; Bollani, L; Pedicino, R; Renzullo, L; Betta, P; Mosca, F; Ferrari, Fabrizio; Magaldi, R; Stronati, M; Farina, D; Italian Task Force for the, Study; Prevention of Neonatal Fungal Infections Italian Society of, Neonatology
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/740881
Citazioni
  • ???jsp.display-item.citation.pmc??? 141
  • Scopus 400
  • ???jsp.display-item.citation.isi??? 358
social impact